Page last updated: 2024-10-31

nafamostat and Diabetic Neuropathies

nafamostat has been researched along with Diabetic Neuropathies in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsuda, Y1
Nakahara, T1
Ueda, K1
Mori, A1
Sakamoto, K1
Ishii, K1

Other Studies

1 other study available for nafamostat and Diabetic Neuropathies

ArticleYear
Effect of nafamostat on N-methyl-D-aspartate-induced retinal neuronal and capillary degeneration in rats.
    Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:12

    Topics: Animals; Basement Membrane; Benzamidines; Capillaries; Diabetic Neuropathies; Excitatory Amino Acid

2012